Views & Analysis Integrating patient insights and real-world data: the future... Drugs development in 2017 looks very different to how it did 10 years ago, and it’s still evolving.
Debates & Insight Sponsored Approval and access: overcoming the final hurdle of drug dev... 2017 is likely to be a year of significant change for pharma brands in Europe. With affordability on the agenda for almost every country in the region, a move toward greater col
Views & Analysis A new age: the real-world development pathway Pharma must be prepared to work collaboratively to establish the best benefit-risk profiles and outcomes.
Views & Analysis Rare diseases and orphan drugs need digital innovation mHealth tech can provide longer-term monitoring for clinical trials.
Views & Analysis Outcomes-based medicine demands real-world evidence RWE must become a fundamental accompaniment to traditional RCT data.
Views & Analysis Astellas wins first Real-World Evidence prize at UK awards UK awards first to introduce a real-world evidence category.
News Senju launches first-in-class dry eye disease drug in Japan Senju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the market.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
